Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor‐Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor Therapy

Background The combination of everolimus (EVE) and exemestane (EXE) is approved for the treatment of patients with metastatic hormone receptor‐positive breast cancer (mHRBC) who progress on nonsteroidal aromatase inhibitor (NSAI) therapy. However, none of the patients enrolled in the trial that led...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The oncologist (Dayton, Ohio) Ohio), 2021-02, Vol.26 (2), p.101-106
Hauptverfasser:	Cook, Madeline M., Al Rabadi, Luai, Kaempf, Andy J., Saraceni, Megan M., Savin, Michael A., Mitri, Zahi I.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antimitotic agents Antineoplastic agents Breast Cancer Care and treatment CDK4/6 inhibitors Cohort studies Drug therapy Everolimus plus exemestane Metastasis Metastatic hormone receptor‐positive breast cancer Patient outcomes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!